Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. CTEV
CTEV logo

CTEV Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
24.540
Open
23.650
VWAP
22.51
Vol
148.37K
Mkt Cap
401.48M
Low
21.334
Amount
3.34M
EV/EBITDA(TTM)
8.77
Total Shares
17.05M
EV
5.07B
EV/OCF(TTM)
49.89
P/S(TTM)
0.37
Claritev Corp, formerly MultiPlan Corporation, is a healthcare technology, data and insights company. The Company’s services include analytics-based services, data & decision science services, network-based services, payment and revenue integrity, end-to-end surprise billing service, and Claritev payments. The Company uses its analytics-based services to price surprise bills and leverages reimbursement data from millions of claims repriced through these services and accepted by providers to assist in negotiations and calculate offers for arbitration when necessary. It uses its payment integrity services on its network claims. The Company’s payment integrity offers advanced code editing, clinical negotiation, itemized bill review, coordination of benefits, subrogation, data mining, Medicare secondary payer validation, and end stage renal disease validation. It provides solutions for the commercial market, government healthcare plans, and property and casualty healthcare payors.
Show More

Events Timeline

(ET)
2026-05-18
12:30:00
Claritev Rallies After Commenting on Last Week's Capitol Forum Report
select
2026-05-18
12:30:00
Shares Up 20% to $16.65
select
2026-05-18
12:30:00
Justice Department Launches Antitrust Investigation into Claritev
select
link
2026-05-18
12:30:00
Claritev Faces DOJ Antitrust Investigation
select
2026-05-18
12:30:00
Claritev Discloses Criminal Antitrust Probe by Justice Department
select
2026-05-18
12:20:00
CTEV Stock Trading Resumes
select
2026-05-18
12:10:00
CTEV Stock Trading Halted Due to Volatility
select
2026-05-13 (ET)
2026-05-13
09:10:00
Claritev Launches PHCS Novera to Address Rising Healthcare Costs
select
2026-05-07 (ET)
2026-05-07
06:40:00
Claritev Q1 Revenue $244.7M, Exceeds Expectations
select

News

Globenewswire
7.0
05-26Globenewswire
Claritev Corporation Faces Antitrust Investigation
  • Antitrust Investigation Launched: On May 14, 2026, the U.S. Department of Justice's antitrust division initiated a criminal price-fixing investigation into Claritev Corporation, focusing on its Data iSight pricing tool, which may violate federal securities laws, potentially impacting the company's reputation and operations.
  • Significant Stock Price Drop: Following the investigation news, Claritev's stock plummeted from $23.47 to $13.87 per share, a 41% decline, directly reflecting market uncertainty regarding the company's future and a loss of investor confidence.
  • Law Firm Involvement: Kirby McInerney LLP is investigating on behalf of Claritev investors to assess the potential for legal claims, indicating heightened scrutiny of the company's senior management's possible misconduct and the implications for shareholder interests.
  • Investor Rights Protection: Although no lawsuit has been filed yet, Kirby McInerney LLP encourages all investors who purchased or acquired Claritev securities to reach out to discuss their rights, emphasizing the necessity and urgency of legal support in light of the ongoing investigation.
Globenewswire
7.0
05-22Globenewswire
Claritev Corporation Faces Antitrust Investigation
  • Antitrust Investigation Launched: On May 14, 2026, the U.S. Department of Justice's antitrust division initiated a criminal price-fixing investigation into Claritev Corporation, focusing on its Data iSight pricing tool, which may violate federal securities laws, impacting the company's reputation and market trust.
  • Significant Stock Price Drop: Following the investigation news, Claritev's stock plummeted from $23.47 per share on May 14 to $13.87 on May 15, representing a 41% decline, which directly affects investor confidence and may lead to subsequent lawsuits.
  • Law Firm Involvement: Kirby McInerney LLP has reminded Claritev investors of the ongoing investigation to determine if claims can be filed, indicating the company faces legal risks that could affect its future operations.
  • Investor Rights Protection: The firm encourages investors who purchased or acquired Claritev securities to contact them to discuss their rights, highlighting the importance of investor protection and potentially impacting the company's future investment appeal.
Globenewswire
7.0
05-21Globenewswire
Claritev Faces Antitrust Investigation Amid Stock Drop
  • Antitrust Investigation Launched: The U.S. Department of Justice's antitrust division initiated a criminal price-fixing investigation into Claritev on May 14, 2026, focusing on its Data iSight pricing tool, which may expose the company to legal liabilities.
  • Significant Stock Drop: Following the investigation news, Claritev's stock plummeted from $23.47 per share on May 14 to $13.87 on May 15, marking a 41% decline, indicating market concerns about the company's future.
  • Investor Rights Protection: Bragar Eagel & Squire is representing Claritev shareholders in investigating potential claims, urging affected investors to contact the firm to discuss their legal rights, highlighting the importance of investor advocacy.
  • Law Firm Background: Bragar Eagel & Squire is a nationally recognized law firm specializing in securities, derivative, and commercial litigation, demonstrating its extensive experience in handling similar cases.
NASDAQ.COM
2.0
05-21NASDAQ.COM
HCW Biologics Stock Surges 129% Amid Concerns
  • HCW Biologics Surge: HCW Biologics Inc. (HCWB) saw its stock price soar over 129% to $2.43 on Wednesday, despite concerns about potential cash shortages, with only $1.22 million on hand as of March 31, 2026, which could hinder future R&D efforts.
  • Silexion Clinical Progress: Silexion Therapeutics Corp. (SLXN) received approval from the Israeli Ministry of Health to initiate its Phase 2/3 trial for SIL204 in locally advanced pancreatic cancer, with shares rising 96.95% to $0.53, reflecting market confidence in its development prospects.
  • Immunovant Positive Data: Immunovant Inc. (IMVT) reported encouraging results from its Phase 2b trial of MVT-1402, with 72.7% of patients showing over 20% symptom improvement after 16 weeks, leading to a 35.26% stock increase to $35.56, indicating strong potential in autoimmune disease treatment.
  • Modular Medical Commercialization: Modular Medical Inc. (MODD) received FDA clearance for its next-generation tubeless insulin patch pump, with initial shipments expected by the end of Q2 2026, resulting in an 18.62% stock rise to $3.95, marking a significant step towards commercialization.
Yahoo Finance
4.5
05-18Yahoo Finance
Healthcare Stocks Rise Slightly on NYSE
  • Healthcare Index Increase: The NYSE Healthcare Index rose by 0.4% on Monday afternoon, indicating a rebound in market confidence towards the healthcare sector, likely influenced by optimistic investor expectations regarding future healthcare policies.
  • Market Trend Analysis: The upward trend in healthcare stocks suggests that despite economic uncertainties, investors remain bullish on the long-term growth potential of the healthcare industry, particularly in the context of new drug development and an aging population.
  • Improved Investor Sentiment: The stable performance of healthcare stocks has led to improved investor sentiment, which may result in increased capital inflows into the sector, further driving the rise in healthcare stocks.
  • Industry Outlook: The ongoing growth in the healthcare sector is likely to attract more investor attention, especially with the dual support of policy backing and technological innovation, indicating that more investment opportunities are expected to emerge in the future.
Newsfilter
7.0
05-18Newsfilter
Claritev Corporation Under Investigation for Possible Securities Law Violations
  • Antitrust Investigation Launched: On May 14, 2026, the U.S. Department of Justice's antitrust division initiated a criminal price-fixing investigation into Claritev Corporation, focusing on the company's Data iSight pricing tool, which could expose the company to significant legal risks.
  • Stock Price Plummets: Following the announcement of the antitrust investigation, Claritev's stock price fell by $4.11 on May 14, 2026, representing a 14.9% decline, closing at $23.47, indicating market concerns about the company's future.
  • Continued Stock Decline: The stock continued to drop in subsequent trading, with a decrease of $8.44 or 35.95% on May 15, 2026, reflecting increasing uncertainty among investors regarding the company's prospects.
  • Investor Rights at Risk: Due to the significant stock price drop, investors in Claritev may face substantial losses, prompting the Law Offices of Howard G. Smith to urge affected investors to contact them for potential claims, highlighting the urgency of legal action.
Wall Street analysts forecast CTEV stock price to rise
3 Analyst Rating
Wall Street analysts forecast CTEV stock price to rise
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
33.00
Averages
62.00
High
90.00
Current: 0.000
sliders
Low
33.00
Averages
62.00
High
90.00
Citi
Buy
upgrade
$21 -> $40
AI Analysis
2026-05-13
Reason
Citi
Price Target
$21 -> $40
AI Analysis
2026-05-13
upgrade
Buy
Reason
In a sector note on U.S. HealthTech & Distribution, Citi raised the firm's price target on Claritev to $40 from $21 and keeps a Buy rating on the shares, citing strong early FY26 momentum with $44M in annual contract value closings and six new logos.
Barclays
Overweight
initiated
$28
2026-04-24
Reason
Barclays
Price Target
$28
2026-04-24
initiated
Overweight
Reason
Barclays initiated coverage of Claritev with an Overweight rating and $28 price target. With the shares down 70% from the peak in September, Claritev's risk/reward skews positive, the analyst tells investors in a research note. The firm believes the company's recent operational momentum is underappreciated in consensus estimates and finds the stock's valuation attractive at current levels.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for CTEV
Unlock Now

Valuation Metrics

The current forward P/E ratio for Claritev Corp (CTEV.N) is 0.00, compared to its 5-year average forward P/E of -3.40. For a more detailed relative valuation and DCF analysis to assess Claritev Corp's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.40
Current PE
0.00
Overvalued PE
-2.18
Undervalued PE
-4.61

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
9.24
Current EV/EBITDA
9.42
Overvalued EV/EBITDA
9.94
Undervalued EV/EBITDA
8.53

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
0.61
Current PS
0.36
Overvalued PS
0.90
Undervalued PS
0.31

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

trade analysis of top five gap upstocks
Intellectia · 61 candidates
Relative Vol: >= 1.50Gap Pattern: GapUpMoving Average Relationship: PriceAboveMA5, PriceAboveMA20
Ticker
Name
Market Cap$
top bottom
AEHL logo
AEHL
Antelope Enterprise Holdings Ltd
6.19M
RXT logo
RXT
Rackspace Technology Inc
1.37B
WEST logo
WEST
Westrock Coffee Co
804.85M
FLNC logo
FLNC
Fluence Energy Inc
4.45B
VRAX logo
VRAX
Virax Biolabs Group Ltd
1.27M
MRAM logo
MRAM
Everspin Technologies Inc
632.85M

Whales Holding CTEV

H
HBK Investments L.P.
Holding
CTEV
+2.61%
3M Return
T
Third Point LLC
Holding
CTEV
+1.51%
3M Return
G
GIC Special Investments Pte. Ltd.
Holding
CTEV
-2.19%
3M Return
T
The Public Investment Fund of The Kingdom of Saudi Arabia
Holding
CTEV
-4.39%
3M Return
H
Hellman & Friedman LLC
Holding
CTEV
-21.73%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Claritev Corp (CTEV) stock price today?

The current price of CTEV is 21.67 USD — it has decreased -7.98

What is Claritev Corp (CTEV)'s business?

Claritev Corp, formerly MultiPlan Corporation, is a healthcare technology, data and insights company. The Company’s services include analytics-based services, data & decision science services, network-based services, payment and revenue integrity, end-to-end surprise billing service, and Claritev payments. The Company uses its analytics-based services to price surprise bills and leverages reimbursement data from millions of claims repriced through these services and accepted by providers to assist in negotiations and calculate offers for arbitration when necessary. It uses its payment integrity services on its network claims. The Company’s payment integrity offers advanced code editing, clinical negotiation, itemized bill review, coordination of benefits, subrogation, data mining, Medicare secondary payer validation, and end stage renal disease validation. It provides solutions for the commercial market, government healthcare plans, and property and casualty healthcare payors.

What is the price predicton of CTEV Stock?

Wall Street analysts forecast CTEV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTEV is62.00 USD with a low forecast of 33.00 USD and a high forecast of 90.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Claritev Corp (CTEV)'s revenue for the last quarter?

Claritev Corp revenue for the last quarter amounts to 244.68M USD, increased 5.77

What is Claritev Corp (CTEV)'s earnings per share (EPS) for the last quarter?

Claritev Corp. EPS for the last quarter amounts to -4.41 USD, increased 0.68

How many employees does Claritev Corp (CTEV). have?

Claritev Corp (CTEV) has 3000 emplpoyees as of May 28 2026.

What is Claritev Corp (CTEV) market cap?

Today CTEV has the market capitalization of 401.48M USD.